<DOC>
	<DOCNO>NCT00235274</DOCNO>
	<brief_summary>The overarch purpose propose study determine Secretin 's ( RG1068 ) psychophysiological effect measure motor learning , affective , inhibitory information processing individual schizophrenia . Motor learn assessed classical eye-blink conditioning procedure , require learn reflexive eye-blink response weak puff air eye .</brief_summary>
	<brief_title>Effects RG1068 ( Secretin ) Information Processing Schizophrenia</brief_title>
	<detailed_description>In recent placebo-controlled , double-blind , multicenter study Secretin refractory schizophrenic , find patient receive Secretin ( 1.0 g/kg ) intravenously , show marked improvement eye blink condition follow infusion . This subject also show clinical improvement &gt; 20 % Total Score Total Negative Score Positive Negative Syndrome Scale ( PANSS ) . Therefore , primary objective study confirm extend observation large group individual schizophrenia . In 24 48 hour experiment , acquisition extinction condition blink response assess participant schizophrenia randomly assign one two double blind treatment group : ( 1 ) subcutaneous saline ( 2 ) subcutaneous Secretin ( 20 ug/kg ) . Enrolled participant remain stable medication regime ( i.e. , psychotropic medication related treatment manipulate ) . Furthermore , give evidence Secretin administration increase amygdala 's activation experimental presentation fear-related facial cue stimulus , wish also investigate effect experimental agent psychophysiological process putatively related amygdala function . Prepulse inhibition widely study paradigm schizophrenia literature , think reflect disruption early sensory-motor gate present individual schizophrenia unaffected biological relative , mediate various limbic structure include amygdala . Therefore , secondary aim , effect Secretin test affect modulation , pre-pulse inhibition , pre-pulse facilitation acoustic startle response use common psychophysiological research procedure . These procedure frequently use laboratory currently approve use IRBs IUPUI IUB .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Secretin</mesh_term>
	<criteria>1 . Able give inform consent 2 . DSMIV diagnosis schizophrenia 3 . 1855 year age 4 . Stable medication &gt; 4 week 1 . Active suicidal ideation 2 . Concurrent DSMIV comorbidity substance dependence 3 . A urine drug screen qualitatively positive control substance 4 . Abnormal hepatic function ( AST ALT &gt; 2.5 X upper limit normal , bilirubin &gt; 1.5 X upper limit normal ) 5 . Abnormal renal function ( BUN creatinine &gt; 1.5 X upper limit normal ) 6 . Abnormal bone marrow function ( WBC &lt; 4 x 103/mm3 , Platelets &lt; 100 x 103/mm3 hemoglobin &lt; 10 g/dl ) 7 . Any history sensitivity ingredient study drug 8 . Clinically significant organic disease include cardiovascular , hepatic , pulmonary , neurologic , renal disease medical condition , serious intercurrent illness , extenuate circumstance , opinion Investigator , would interfere performance interpretability , put patient risk , study procedure . 9 . Women pregnant , breastfeeding , refuse use adequate birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Secretin</keyword>
</DOC>